Clinical Trial Details
— Status: Not yet recruiting
Administrative data
NCT number |
NCT06142968 |
Other study ID # |
ACLF |
Secondary ID |
|
Status |
Not yet recruiting |
Phase |
|
First received |
|
Last updated |
|
Start date |
December 2023 |
Est. completion date |
October 2026 |
Study information
Verified date |
November 2023 |
Source |
Assiut University |
Contact |
Nardin Nadi Roshdy Saweres, Master |
Phone |
01281129495 |
Email |
lollaz.fabio[@]gmail.com |
Is FDA regulated |
No |
Health authority |
|
Study type |
Observational
|
Clinical Trial Summary
ACLF is a distinct syndrome that is different from chronic progressive hepatic
decompensation. In most cases of ACLF, patients present initially with clinical
manifestations of a decompensating event, usually renal impairment, worsening of abdominal
ascites, jaundice or Hepatic encephalopathy (HE) and often precipitated by bacterial
infection.
Description:
Liver cirrhosis is the result of progressive fibrosis in patients with chronic liver disease
of any etiology, and is associated with a poor prognosis, once hepatic decompensation starts.
Cirrhosis has two main phases: the compensated phase, where patients maintain preserved liver
synthetic function and have no significant extrahepatic organ impairment; this is to be
compared with a decompensated phase, where increasing ascites and loss of liver synthetic
function, together with presentation with other organ impairment, are common clinical
presentations. Renal failure, hepatic encephalopathy (HE), recurrent infections and upper
gastrointestinal bleeding from worsening portal hypertension are considered end- stage
complications of decompensated cirrhosis. The term acute- on- chronic liver failure (ACLF) is
used to describe the clinical syndrome where acute hepatic decompensation leads to organ
failures in the setting of liver cirrhosis.
Although there is not a universal agreement about the definition of acute on chronic liver
failure (ACLF), there is a wide agreement that ACLF is a distinct syndrome that is different
from chronic progressive hepatic decompensation. In most cases of ACLF, patients present
initially with clinical manifestations of a decompensating event, usually renal impairment,
worsening of abdominal ascites, jaundice or Hepatic encephalopathy (HE) and often
precipitated by bacterial infection.
In the CANONIC study, ACLF was defined as 'an acute deterioration of pre- existing chronic
liver disease, sometimes related to a clear precipitating event, and associated with
increased mortality at 28 days.
The North American consortium for studying liver disease (NACSELD) proposed another
definition of ACLF that defines it as 'a condition in patients with underlying chronic liver
disease with or without cirrhosis that is associated with mortality within 3 months in the
absence of treatment of the underlying liver disease, liver support, or liver
transplantation'.
Currently, the term ACLF is still a relatively new entity that has not been very well studied
or investigated in our medical research environment. There are no major studies that aimed at
looking at the incidence of ACLF in our medical settings.